Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081817 | 0.90 | KDM4E (0.31) | KDM4EALDH1A1 | |
| SCHEMBL16631582 | 0.85 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL18081947 | 0.84 | KDM4E (0.36) | KDM4EALDH1A1KMT2A | |
| SCHEMBL16631601 | 0.83 | KDM4E (0.34) | KDM4EALDH1A1KMT2APDE3BPDE3A | |
| SCHEMBL18081772 | 0.81 | KDM4E (0.41) | KDM4EALDH1A1KMT2APDE3BPDE3A | |
| SCHEMBL18081944 | 0.81 | KDM4E (0.39) | KDM4EALDH1A1KMT2A | |
| SCHEMBL18081789 | 0.80 | — | — | |
| SCHEMBL18081828 | 0.80 | KDM4E (0.33) | KDM4EALDH1A1ADORA2AADORA1 | |
| SCHEMBL18081977 | 0.78 | KDM4E (0.31) | KDM4EALDH1A1 | |
| SCHEMBL18081845 | 0.77 | KDM4E (0.33) | KDM4EALDH1A1KMT2APDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | KDM4E 4689/4885ALDH1A1 4189/4885KMT2A 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.